查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1908695

癌症免疫療法市場規模、佔有率和趨勢分析報告：按產品、應用、分銷管道、最終用途、地區和細分市場預測（2026-2033 年）

Cancer Immunotherapy Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibodies, Immunomodulators), By Application, By Distribution Channel, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

癌症免疫療法市場概況

全球癌症免疫療法市場預計到 2025 年將價值 1,532.7 億美元，預計到 2033 年將達到 3,058 億美元。

預計從2026年到2033年，該市場將以9.02%的複合年成長率成長。癌症發生率的上升是推動市場成長的關鍵因素。

根據《美國癌症協會日誌，預計到2024年，美國將新增約200萬例癌症病例，並有611,720例癌症死亡病例。製藥公司研發活動的增加、技術的進步以及新藥的問世預計將推動預測期內癌症免疫療法產業的成長。癌症發生率的上升正在推動癌症免疫療法市場的需求。根據國際癌症研究機構（IARC）的估計，2020年全球確診癌症病例約1,929萬例，預計到2030年將增加至2,458萬例。人口疾病負擔的顯著增加預計將推動市場成長。

預計在預測期內，新型免疫療法的核准不斷增加將推動市場成長。例如，2024年12月，Astra Zeneca的免疫療法Imfinzi（Durvalumab）成為首個也是目前唯一核准治療鉑類化療和放射線治療後病情未進展的局限期小細胞肺癌（LS-SCLC）成人患者的治療方法。同樣，患者對皮下給藥方式的偏好日益成長也推動了市場成長。 2024年9月，FDA核准了TECENTRIQ Hybrezza，這是首個皮下注射的PD-(L)1抑制劑，標誌著癌症免疫療法領域的重大進展。該製劑為患者提供了更快捷的治療選擇（7分鐘，而靜脈注射則需要30-60分鐘），同時保持了與靜脈注射注射相當的安全性和有效性。

主要企業的多項策略措施預計也將有助於推動市場需求。例如，2023年9月，Imathys與Moderna達成策略合作，共同開發腫瘤藥物。該合作包括評估Imathys的PRAME203 TCRT與Moderna的MARTE mRNA癌症疫苗的聯合治療。此外，2023年8月，FBD Biologics與上海復宏漢霖生物技術有限公司達成策略合作，共同推動新型免疫療法的研發。這些進展正在推動市場成長。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 癌症免疫療法市場變數、趨勢與範圍

  • 市場譜系展望
    • 母市場展望
    • 相關及配套市場展望
  • 市場動態
  • 癌症免疫療法市場分析工具
    • 產業分析：波特五力模型
    • PESTEL 分析

第4章 癌症免疫療法市場：產品估算與趨勢分析

  • 按產品分類的市場佔有率（2025 年和 2033 年）
  • 全球癌症免疫療法市場：產品展望
  • 市場規模、預測與趨勢分析（2021-2033）
    • 單株抗體
    • 免疫調節劑
    • 溶瘤病毒療法和癌症疫苗

第5章 癌症免疫療法市場：按應用分類的估計和趨勢分析

  • 按應用領域分類的市場佔有率（2025 年和 2033 年）
  • 全球癌症免疫療法市場：按應用領域分類的展望
  • 市場規模、預測與趨勢分析（2021-2033）
    • 肺癌
    • 乳癌
    • 大腸直腸癌
    • 惡性黑色素瘤
    • 攝護腺癌
    • 頭頸癌
    • 卵巢癌
    • 胰臟癌
    • 其他

第6章 癌症免疫療法市場：按分銷管道分類的估算和趨勢分析

  • 按分銷管道分類的市場佔有率（2025 年和 2033 年）
  • 全球癌症免疫療法市場：分銷前景
  • 以下市場規模、預測與趨勢分析（2021-2033）：
    • 醫院藥房
    • 零售藥房
    • 網路藥房

第7章 癌症免疫療法市場：依最終用途分類的估算與趨勢分析

  • 按最終用途分類的市場佔有率（2025 年和 2033 年）
  • 全球癌症免疫療法市場：按最終用途分類的展望
  • 市場規模、預測與趨勢分析（2021-2033）
    • 醫院和診所
    • 癌症研究中心
    • 其他

第8章 癌症免疫療法市場：區域估算與趨勢分析

  • 區域市場佔有率分析（2025 年和 2033 年）
  • 區域市場概覽
  • 全球市場概覽（按地區分類）
  • 市場規模及預測趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 對主要市場參與企業近期趨勢和影響的分析
  • 公司/競爭格局分類
  • 供應商概況
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2025
    • Pfizer Inc.
    • AstraZeneca
    • Merck &Co., Inc
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Lilly
    • Johnson &Johnson Services, Inc
    • Immunocore, Ltd
Product Code: GVR-1-68038-693-6

Cancer Immunotherapy Market Summary

The global cancer immunotherapy market size was estimated at USD 153.27 billion in 2025 and is projected to reach USD 305.80 billion by 2033, growing at a CAGR of 9.02% from 2026 to 2033. The increasing prevalence of cancer is a significant factor driving market growth.

According to the American Cancer Society Journal, in the U.S., about 2 million new cancer cases and 611,720 cancer deaths are estimated to occur in the year 2024. Growing R&D activities by pharmaceutical companies, technological advancements, and the introduction of novel drugs are expected to drive the growth of the cancer immunotherapy industry in the forecast period. The increasing prevalence of cancer is boosting the demand for the cancer immunotherapy market. According to the International Agency for Research on Cancer (IARC) estimates, in the year 2020, there were about 19.29 million cancer cases, which is estimated to increase to 24.58 million cases by 2030. This significant increase in the disease burden on the population is expected to drive the market growth.

Rising approval of novel immunotherapies is expected to propel the market growth over the forecast period. For instance, in December 2024, AstraZeneca's immunotherapy drug Imfinzi (durvalumab) became the first and only approved regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy. Similarly, the increasing patient preference for subcutaneous drug administration is fueling market growth. In September 2024, the FDA approved Tecentriq Hybreza, the first subcutaneous PD-(L)1 inhibitor, representing a significant breakthrough in cancer immunotherapy. This formulation offers patients a faster treatment option (7 minutes versus 30-60 minutes for intravenous infusion) while maintaining the same safety and efficacy as the intravenous version.

Various strategic initiatives undertaken by major players are also anticipated to facilitate the market demand. For instance, in September 2023, Immatics and Moderna strategically collaborated to develop the Oncology Therapeutics. The collaboration includes an assessment of Immatics' investigational PRAME203 TCRT in combination with the MARTE mRNA cancer vaccine being developed by Moderna. Moreover, in August 2023, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. entered into a strategic collaboration to boost the development of new immunotherapies. These aspects are driving the market growth.

Global Cancer Immunotherapy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer immunotherapy market report based on product, application, distribution channel, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Monoclonal Antibodies
  • Immunomodulators
  • Oncolytic Viral Therapies and Cancer Vaccines
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Clinics
  • Cancer Research Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Distribution
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Application
    • 2.2.3. Distribution
    • 2.2.4. End Use
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Immunotherapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Growing R&D activities by pharmaceutical companies
      • 3.2.1.3. Technological advancements and introduction of novel drugs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk of side effects associated with the treatment
      • 3.2.2.2. High cost of therapy and unfavourable reimbursement scenario
  • 3.3. Cancer Immunotherapy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cancer Immunotherapy Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Cancer Immunotherapy Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Monoclonal Antibodies
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Immunomodulators
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Oncolytic Viral Therapies and Cancer Vaccines
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Cancer Immunotherapy Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Cancer Immunotherapy Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Lung Cancer
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Breast Cancer
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. Colorectal Cancer
      • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.4. Melanoma
      • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.5. Prostate Cancer
      • 5.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.6. Head and Neck Cancer
      • 5.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.7. Ovarian Cancer
      • 5.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.8. Pancreatic Cancer
      • 5.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.9. Others
      • 5.4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Cancer Immunotherapy Market: Distribution Estimates & Trend Analysis

  • 6.1. Distribution Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Cancer Immunotherapy Market by Distribution Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Hospital Pharmacy
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 6.4.2. Retail Pharmacy
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Online Pharmacy
      • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Cancer Immunotherapy Market: End Use Estimates & Trend Analysis

  • 7.1. Distribution Market Share, 2025 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Cancer Immunotherapy Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 7.4.1. Hospitals & Clinics
      • 7.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 7.4.2. Cancer Research Centers
      • 7.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. Others
      • 7.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Cancer Immunotherapy Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2025
    • 9.3.4. Pfizer Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. AstraZeneca
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Merck & Co., Inc
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. F. Hoffmann-La Roche Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Bristol-Myers Squibb Company
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Novartis AG
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Lilly
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Johnson & Johnson Services, Inc
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Immunocore, Ltd
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 4 North America Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 5 North America Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 6 North America Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 7 U.S. Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 8 U.S. Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 9 U.S. Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 10 U.S. Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 12 Canada Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 13 Canada Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 14 Canada Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Mexico Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 16 Mexico Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 17 Mexico Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 18 Mexico Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Europe Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 20 Europe Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 21 Europe Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 22 Europe Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 23 Europe Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Germany Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 25 Germany Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 26 Germany Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 27 Germany Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 28 UK Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 29 UK Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 30 UK Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 31 UK Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 32 France Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 33 France Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 34 France Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 35 France Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 36 Italy Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 37 Italy Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 38 Italy Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 39 Italy Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Spain Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 41 Spain Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 42 Spain Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 43 Spain Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 44 Denmark Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 45 Denmark Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 46 Denmark Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 47 Denmark Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 48 Sweden Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 49 Sweden Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 50 Sweden Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 51 Sweden Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 52 Norway Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 53 Norway Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 54 Norway Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 55 Norway Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 56 Asia Pacific Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 61 China Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 62 China Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 63 China Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 64 China Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Japan Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 66 Japan Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 67 Japan Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 68 Japan Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 69 India Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 70 India Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 71 India Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 72 India Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 73 South Korea Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 74 South Korea Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 75 South Korea Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 76 South Korea Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 77 Australia Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 78 Australia Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 79 Australia Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 80 Australia Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 81 Thailand Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 82 Thailand Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 83 Thailand Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 84 Thailand Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 85 Latin America Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 86 Latin America Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 87 Latin America Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 88 Latin America Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 89 Latin America Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 90 Brazil Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 91 Brazil Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 92 Brazil Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 93 Brazil Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 94 Argentina Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 95 Argentina Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 96 Argentina Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 97 Argentina Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 98 MEA Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 99 MEA Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 100 MEA Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 101 MEA Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 102 MEA Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 103 South Africa Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 104 South Africa Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 105 South Africa Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 106 South Africa Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 107 Saudi Arabia Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 111 UAE Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 112 UAE Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 113 UAE Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 114 UAE Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 115 Kuwait Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 116 Kuwait Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 117 Kuwait Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 118 Kuwait Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Cancer Immunotherapy market: market outlook
  • Fig. 14 Cancer Immunotherapy competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Cancer Immunotherapy market driver impact
  • Fig. 20 Cancer Immunotherapy market restraint impact
  • Fig. 21 Cancer Immunotherapy market strategic initiatives analysis
  • Fig. 22 Cancer Immunotherapy market: Product movement analysis
  • Fig. 23 Cancer Immunotherapy market: Product outlook and key takeaways
  • Fig. 24 Monoclonal Antibodies market estimates and forecast, 2021 - 2033
  • Fig. 25 Immunomodulators market estimates and forecast, 2021 - 2033
  • Fig. 26 Oncolytic Viral Therapies and Cancer Vaccines market estimates and forecast, 2021 - 2033
  • Fig. 27 Cancer Immunotherapy Market: Application movement analysis
  • Fig. 28 Cancer Immunotherapy market: Application outlook and key takeaways
  • Fig. 29 Lung Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 30 Breast Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 31 Colorectal Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 32 Melanoma market estimates and forecasts, 2021 - 2033
  • Fig. 33 Prostate Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 34 Head and Neck Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 35 Ovarian Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 36 Pancreatic Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 37 Others market estimates and forecasts, 2021 - 2033
  • Fig. 38 Cancer Immunotherapy market: Distribution movement analysis
  • Fig. 39 Cancer Immunotherapy market: Distribution outlook and key takeaways
  • Fig. 40 Hospital Pharmacy market estimates and forecasts, 2021 - 2033
  • Fig. 41 Retail Pharmacy market estimates and forecasts, 2021 - 2033
  • Fig. 42 Online Pharmacy market estimates and forecasts, 2021 - 2033
  • Fig. 43 Cancer Immunotherapy market: End Use movement analysis
  • Fig. 44 Cancer Immunotherapy market: End Use outlook and key takeaways
  • Fig. 45 Hospitals & Clinics market estimates and forecasts, 2021 - 2033
  • Fig. 46 Cancer Research Centers market estimates and forecasts, 2021 - 2033
  • Fig. 47 Others market estimates and forecasts, 2021 - 2033
  • Fig. 48 Global Cancer Immunotherapy market: Regional movement analysis
  • Fig. 49 Global Cancer Immunotherapy market: Regional outlook and key takeaways
  • Fig. 50 Global Cancer Immunotherapy market share and leading players
  • Fig. 51 North America market share and leading players
  • Fig. 52 Europe market share and leading players
  • Fig. 53 Asia Pacific market share and leading players
  • Fig. 54 Latin America market share and leading players
  • Fig. 55 Middle East & Africa market share and leading players
  • Fig. 56 North America: SWOT
  • Fig. 57 Europe SWOT
  • Fig. 58 Asia Pacific SWOT
  • Fig. 59 Latin America SWOT
  • Fig. 60 MEA SWOT
  • Fig. 61 North America, by country
  • Fig. 62 North America
  • Fig. 63 North America market estimates and forecasts, 2021 - 2033
  • Fig. 64 U.S.
  • Fig. 65 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 66 Canada
  • Fig. 67 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 68 Mexico
  • Fig. 69 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 70 Europe
  • Fig. 71 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 72 UK
  • Fig. 73 UK market estimates and forecasts, 2021 - 2033
  • Fig. 74 Germany
  • Fig. 75 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 76 France
  • Fig. 77 France market estimates and forecasts, 2021 - 2033
  • Fig. 78 Italy
  • Fig. 79 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 80 Spain
  • Fig. 81 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 82 Denmark
  • Fig. 83 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 84 Sweden
  • Fig. 85 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 86 Norway
  • Fig. 87 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 88 Asia Pacific
  • Fig. 89 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 90 China
  • Fig. 91 China market estimates and forecasts, 2021 - 2033
  • Fig. 92 Japan
  • Fig. 93 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 94 India
  • Fig. 95 India market estimates and forecasts, 2021 - 2033
  • Fig. 96 Thailand
  • Fig. 97 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 98 South Korea
  • Fig. 99 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 100 Australia
  • Fig. 101 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 102 Latin America
  • Fig. 103 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 104 Brazil
  • Fig. 105 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 106 Argentina
  • Fig. 107 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 108 Middle East and Africa
  • Fig. 109 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 110 South Africa
  • Fig. 111 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 112 Saudi Arabia
  • Fig. 113 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 114 UAE
  • Fig. 115 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 116 Kuwait
  • Fig. 117 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 118 Market share of key market players- Cancer Immunotherapy market